查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1609938

日本糖尿病市场报告：2024-2032

Japan Diabetes Market Report: 2024-2032
出版日期: | 出版商: IMARC | 英文 115 Pages | 商品交期: 5-7个工作天内

价格

2023 年日本糖尿病市场IMARC Group达到 54 亿美元。该市场主要由老年人口不断增长、糖尿病患病率增加、政府支持性倡议增加的医疗保健支出以及治疗方案的技术进步所推动。

日本糖尿病市场分析：

主要市场驱动因素：由于生活方式的改变和人口老化，日本糖尿病盛行率不断上升，这是一个主要的成长诱导因素。此外，最近的研究表明，糖尿病患者人数仍在增长，这正在增加日本糖尿病市场的需求。此外，政府也资助并执行了多项健康倡议，以加强糖尿病的治疗和管理。其中包括糖尿病治疗补助和鼓励市场扩张的公共卫生措施。

主要市场趋势：先进的糖尿病护理技术，如胰岛素帮浦和连续血糖监测仪 (CGM) 越来越受欢迎。此外，市场正在见证个人化治疗计划和定製药物的趋势，这是由对遗传变量和独特患者需求的更多研究推动的，以提供更高效和专业的糖尿病管理解决方案。

竞争格局：日本糖尿病市场由大型国际製药和医疗器材企业主导，其广泛的产品和尖端技术有助于他们保持竞争力。此外，日本公司也针对日本患者的需求提供创新和客製化解决方案。

挑战与机会：市场面临的挑战包括严格的监管规定和新型糖尿病疗法的漫长审批程序。另一方面，不断增长的老年人口为开发专门针对该人群的糖尿病治疗和管理计划提供了巨大的机会。此外，远距医疗和行动健康应用程式等数位健康技术的发展为更好的患者参与和糖尿病管理创造了新的可能性。

日本糖尿病市场趋势：

糖尿病盛行率上升

日本糖尿病市场的成长是由糖尿病发病率上升所推动的。根据国际糖尿病联盟（IDF）报告，截至2021年，全国有93,187,400人，成人糖尿病盛行率为11.8%，即11,004,999例。因此，由于对完整的糖尿病护理解决方案（包括尖端药物和监测设备）的需求不断增加，市场正在扩大。此外，越来越多的患者迫使製药公司和医疗保健专业人员创造并提供广泛的治疗替代方案，以满足患者的多样化需求。此外，糖尿病病例的增加增加了针对糖尿病的医疗保健服务，试图提高患者的治疗效果和生活品质。因此，这一趋势推动了抗糖尿病药物的销售，并推动了创新血糖监测技术的市场，这些技术有望提供更准确和用户友好的选择，从而创造了积极的日本糖尿病市场前景。

老年人口不断增加

根据总务省报道，截至2023年9月15日，日本65岁及以上老年人口达到3,622.7万人。此外，老年人更容易患第 2 型糖尿病，这增加了对专门糖尿病管理计划和产品的需求。人口的这种变化促使医疗保健组织和临床医生专注于老年糖尿病的治疗，从而根据老年人群的需求在药物治疗、营养指导和患者教育方面取得了进展。此外，人口老化影响了一些需求的服务和产品，这些服务和产品使用简单且侵入性低，非常适合老年患者，并增加了必要的糖尿病治疗量。

支持性政府措施和医疗保健支出

糖尿病市场是由日本政府积极的医疗保健支出推动的，其中包括用于治疗糖尿病等慢性疾病的大量预算。根据Frontiers 报道，2020 年，日本的全国医疗支出猛增至43 兆日圆（3,040 亿美元），几乎是1990 年以来的两倍。 。此外，政府确保有足够的资金用于糖尿病护理，这使得治疗更容易获得且价格更合理。这些计划涵盖从复杂的治疗选择到初级预防的各个方面，糖尿病护理的基础正在改善。此外，许多政府措施集中在筛检和公共卫生运动，以降低糖尿病盛行率，同时改善社区层级的管理，这些措施正在影响市场的成长。因此，这些全面的健康政策透过提高意识和早期发现，同时将先进的糖尿病照护纳入公共卫生系统，支持日本糖尿病市场的成长。

日本糖尿病市场细分：

按细分市场细分：

口服抗糖尿病药

胰岛素

胰岛素占大部分市场份额

由于老龄化人群中糖尿病盛行率的增加以及越来越多地采用胰岛素疗法来进行有效的血糖管理，胰岛素占据了相当大的市场份额。此外，日本的医疗保健系统以其高效而闻名，广泛支持糖尿病护理，使胰岛素治疗的普及成为可能。此外，市场受益于胰岛素配方和输送系统的进步，这提高了患者的依从性和结果。此外，日本政府积极主动的健康措施旨在提高糖尿病意识和筛检，进一步推动对胰岛素的需求。此外，国内製药公司与全球糖尿病护理领导者之间的合作也推动了该领域的成长，旨在创新和扩大针对日本患者独特需求的尖端胰岛素解决方案的可用性。因此，主要参与者正在推出先进的产品变体来满足这些需求。例如，2023 年 3 月，Health2Sync 在日本东京和台湾台北宣布其 Health2Sync 应用程式最近更新，现在包括来自 Mallya Cap 的胰岛素资料，Mallya Cap 是由 Biocorp 创建并由 Novo 在日本销售的胰岛素笔连接设备诺德。此次合作首次整合了此类资料，旨在透过追踪胰岛素注射记录等各种健康指标来帮助接受胰岛素治疗的患者。由于这些创新，日本糖尿病市场预测显示胰岛素细分市场将继续主导市场。

竞争格局：

市场研究报告也对市场竞争格局进行了全面分析。已提供所有主要公司的详细资料。

目前，市场上的主要参与者正在透过策略合作、先进的研发 (R&D) 措施以及改善糖尿病管理的教育计划积极促进成长。此外，诺和诺德和赛诺菲等公司正大力投资开发下一代胰岛素疗法和血糖监测系统，以满足日本患者的特定需求，从而占据日本糖尿病市场份额。这些公司与当地医疗保健提供者密切合作，以确保其产品的广泛分销和融入日常医疗实践中。此外，这些市场领导者支持广泛的患者教育活动，以提高对有效疾病管理所需的糖尿病症状、治疗选择和生活方式调整的认识。这些综合策略增强了他们的市场地位，并为改善日本患者的治疗效果做出了重大贡献。例如，2023 年3 月29 日，马里兰州安斯泰来製药公司(Astellas Pharma Inc.) 宣布与Roche Diabetes Care Japan Co., Ltd. 建立合作伙伴关係。 -Chek Guide Me 血糖监测系统的开发和商业化。 BlueStar 是一种经 FDA 批准的用于管理糖尿病的数位健康解决方案，由 Welldoc, Inc. 开发，在美国和加拿大上市。安斯泰来和 Welldoc 正在合作推动 BlueStar 在日本的发展。安斯泰来计划在未来为这款整合医疗产品寻求监管部门的批准和报销。

日本糖尿病市场新闻：

2023 年 4 月 18 日，礼来日本公司和三菱田边製药公司 (MTPC) 宣布在日本推出 Mounjaro 皮下注射 2.5 mg / 5 mg ATEOS，这是一种有前景的 2 型糖尿病治疗替代方案。

2024 年 5 月 22 日，三菱化学集团旗下、总部位于日本大阪中央区的三菱田边製药公司 (MTPC) 宣布推出 SGLT2 抑制剂 CANAGLU(R) OD 片 100 毫克，提供一种新的治疗方法2 型糖尿病的选择。 CANAGLU(R) OD 片剂的设计只需少量水分（例如唾液）即可快速崩解，更容易摄取。这项功能对于需要持续用药的 2 型糖尿病患者特别有益，因为它提高了治疗的便利性和依从性。

本报告回答的关键问题：

  • 到目前为止，日本糖尿病市场的表现如何，未来几年将如何表现？
  • COVID-19 对日本糖尿病市场有何影响？
  • 日本糖尿病市场的细分情况如何？
  • 日本糖尿病市场价值链的各个阶段是什么？
  • 日本糖尿病市场的关键驱动因素和挑战是什么？
  • 日本糖尿病市场的结构如何？
  • 日本糖尿病市场的竞争程度如何？

本报告回答的关键问题：

  • 到目前为止，日本糖尿病市场的表现如何，未来几年将如何表现？
  • COVID-19 对日本糖尿病市场有何影响？
  • 日本糖尿病市场的细分情况如何？
  • 日本糖尿病市场价值链的各个阶段是什么？
  • 日本糖尿病市场的关键驱动因素和挑战是什么？
  • 日本糖尿病市场的结构如何？
  • 日本糖尿病市场的竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：糖尿病概述

  • 什么是糖尿病？
  • 糖尿病诊断与治疗
    • 诊断
    • 治疗
  • 糖尿病併发症

第 6 章：日本糖尿病流行病学

  • 糖尿病人口和盛行率
  • 人口和盛行率：按糖尿病类型（1 型和 2 型）
  • 人口和盛行率：按地区
  • 人口及盛行率：依性别分类
  • 人口和盛行率：依年龄组别

第 7 章：日本糖尿病市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测
  • SWOT分析
    • 概述
    • 优势
    • 弱点
    • 机会
    • 威胁
  • 价值链分析
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 市场区隔：按细分市场
    • 日本口服降血糖药市场
      • 历史市场趋势
      • 市场区隔：依类别
      • 关键参与者的市场份额
      • 市场预测
    • 日本胰岛素市场
      • 历史市场趋势
      • 市场区隔：依类别
      • 关键参与者的市场份额
      • 市场预测

第 8 章：竞争格局

  • 市场结构
  • 关键参与者简介
Product Code: SR112024A561

The Japan diabetes market size reached US$ 5.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.3 Billion by 2032, exhibiting a growth rate (CAGR) of 3.3% during 2024-2032. The market is primarily driven by the growing geriatric population, increased prevalence of diabetes, enhanced healthcare spending with supportive government initiatives, and technological advancements in treatment options.

Japan Diabetes Market Analysis:

Major Market Drivers: The rising prevalence of diabetes in Japan due to the changing lifestyles and an aging population represents a major growth-inducing factor. In addition, recent research indicates that the diabetic patient population is still growing, which is increasing the Japan diabetes market demand. Besides, the government has funded and executed several health initiatives to enhance the treatment and management of diabetes. These include diabetes treatment subsidies and public health initiatives that encourage market expansion.

Key Market Trends: Advanced diabetes care technology like insulin pumps and continuous glucose monitors (CGMs) are becoming more popular. Moreover, the market is witnessing a trend toward individualized treatment plans and customized medicines, which is driven by greater research into genetic variables and unique patient demands to deliver more efficient and specialized diabetes management solutions.

Competitive Landscape: The Japanese diabetes market is dominated by giant international pharmaceutical and medical device businesses, as their wide range of products and cutting-edge technology help them to stay competitive. Additionally, Japanese companies are offering innovations and customized solutions specific to the requirements of Japanese patients.

Challenges and Opportunities: Challenges in the market include stringent regulatory regulations and protracted approval procedures for novel diabetic therapies. On the other hand, the growing geriatric population offers substantial opportunities for the development of diabetes treatment and management programs specifically designed for this demographic. Besides, the development of digital health technologies, such as telemedicine and mobile health apps, creates new possibilities for better patient engagement and diabetes management.

Japan Diabetes Market Trends:

Rising Diabetes Prevalence

The growth of the diabetes market in Japan is driven by the rising incidence of diabetes. According to the International Diabetes Federation (IDF) reports, with 93,187,400 individuals in the country as of 2021, the prevalence rate of diabetes is 11.8% or 11,004,999 cases among adults. As a result, the market is expanding due to the increasing need for complete diabetes care solutions, which include cutting-edge drugs and monitoring equipment. Moreover, pharmaceutical businesses and healthcare professionals are compelled by the increasing number of patients to create and offer a wide array of treatment alternatives that address the diverse demands of their patients. In addition, the rise in diabetes cases has increased diabetes-specific healthcare services that attempt to enhance patient outcomes and quality of life. Hence, this trend has propelled the sales of anti-diabetic medications and boosted the market for innovative glucose monitoring technologies that promise more accurate and user-friendly options, thus creating a positive Japan diabetes market outlook.

Growing Geriatric Population

As reported by the Ministry of Internal Affairs and Communications, Japan's elderly population, those aged 65 and above, reached 36,227 thousand as of September 15, 2023. Moreover, the proportion of seniors in the overall population increased by 0.1% points to 29.1%, the highest percentage ever recorded. Additionally, the elderly are more susceptible to type 2 diabetes, which escalates the need for specialized diabetes management programs and products. This change in the population motivates healthcare organizations and clinicians to concentrate on the treatment of geriatric diabetes, resulting in advancements in medication therapy, nutritional guidance, and patient education customized to the needs of the geriatric population. Besides, the aging population influences several services and products that are in demand, offer simple use and low invasiveness, which are ideal for senior patients, and increase the volume of diabetic treatments that are necessary.

Supportive Government Initiatives and Healthcare Spending

The diabetes market is driven by the government of Japan's aggressive approach to healthcare spending, which includes a sizeable budget for treating chronic illnesses like diabetes. According to Frontiers, in 2020, Japan's national medical spending skyrocketed to 43 Trillion yen (304 Billion USD), nearly doubling from past figures since 1990. This indicates an increase in the nation's gross domestic output from 4.6% to 8.0%. In addition, the government ensures that enough money is spent on diabetes care, which makes treatments more accessible and reasonably priced. The foundation of diabetes care is being improved due to these programs, which cover everything from sophisticated treatment choices to primary prevention. In addition, numerous government initiatives concentrated on screenings and public health campaigns to lower the prevalence of diabetes while improving its management at the community level are influencing the market growth. Hence, these comprehensive health policies support Japan diabetes market growth by increasing awareness and early detection while integrating advanced diabetes care into the public health system.

Japan Diabetes Market Segmentation:

Breakup by Segment:

Oral Antidiabetics

Insulin

Insulin accounts for the majority of the market share

Insulin reflects a substantial portion of the market share due to the increasing prevalence of diabetes among the aging population and the rising adoption of insulin therapies for effective glucose management. Additionally, Japan's healthcare system, renowned for its efficiency, extensively supports diabetes care, enabling widespread access to insulin treatments. Moreover, the market benefits from advancements in insulin formulations and delivery systems, which enhance patient adherence and outcomes. Besides, the Japanese government's proactive health initiatives aim to improve diabetes awareness and screening, further driving the demand for insulin. Furthermore, this segment's growth is also fueled by collaborations between domestic pharmaceutical companies and global diabetes care leaders, aiming to innovate and expand the availability of cutting-edge insulin solutions tailored to the unique needs of Japanese patients. Hence key players are introducing advanced product variants to meet these needs. For instance, in March 2023, in Tokyo Japan, and Taipei, Taiwan, Health2Sync, announced the recent update of its Health2Sync App now including insulin data from the Mallya Cap, a connected device for insulin pens created by Biocorp and marketed in Japan by Novo Nordisk. This collaboration introduces the world's first integration of this type of data and is designed to aid patients undergoing insulin treatment by tracking various health metrics, such as insulin injection records. Due to these innovations, the Japan diabetes market forecast states that insulin segment will continue to dominate the market.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have been provided.

At present, key players in the market are actively enhancing growth through strategic collaborations, advanced research and development (R&D) initiatives, and educational programs to improve diabetes management. Additionally, companies like Novo Nordisk and Sanofi are investing heavily in the development of next-generation insulin therapies and glucose monitoring systems tailored to meet the specific needs of Japanese patients, thus accounting for the Japan diabetes market share. These firms collaborate closely with local healthcare providers to ensure broad distribution and integration of their products into daily medical practice. Furthermore, these market leaders support extensive patient education campaigns to increase awareness about diabetes symptoms, treatment options, and lifestyle adjustments necessary for effective disease management. These comprehensive strategies strengthen their market position and significantly contribute to improving patient outcomes in Japan. For instance, on 29 March 2023, Maryland, Astellas Pharma Inc. announced its partnership with Roche Diabetes Care Japan Co., Ltd. This partnership focuses on the development and commercialization of the globally recognized Accu-Chek Guide Me blood glucose monitoring system, noted for its high accuracy, in conjunction with BlueStar(R)*1. BlueStar, an FDA-approved digital health solution for managing diabetes, is developed by Welldoc, Inc. and is available in the U.S. and Canada. Astellas and Welldoc are collaboratively advancing BlueStar's development in Japan. Astellas plans to seek regulatory approval and reimbursement for this integrated medical product in the future.

Japan Diabetes Market News:

18 April 2023, Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation (MTPC) have declared the introduction of the Mounjaro subcutaneous injection 2.5 mg / 5 mg ATEOS in Japan which represents a promising treatment alternative for type 2 diabetes.

22 May 2024, Mitsubishi Tanabe Pharma Corporation (MTPC), part of the Mitsubishi Chemical Group and headquartered in Chuo-ku, Osaka, Japan, announced the release of the SGLT2 inhibitor CANAGLU(R) OD Tablets 100 mg, to provide a new treatment option for type 2 diabetes mellitus. The CANAGLU(R) OD Tablets are designed to disintegrate quickly with just a slight amount of moisture, such as saliva, facilitating easier ingestion. This feature is particularly beneficial for individuals with type 2 diabetes requiring continuous medication, as it enhances convenience and adherence to treatment.

Key Questions Answered in This Report:

  • How has the Japan diabetes market performed so far, and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan diabetes market?
  • What is the breakup of the Japan diabetes market on the basis of segment?
  • What are the various stages in the value chain of the Japan diabetes market?
  • What are the key driving factors and challenges in the Japan diabetes market?
  • What is the structure of the Japan diabetes market, and who are the key players?
  • What is the degree of competition in the Japan diabetes market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Diabetes Disease Overview

  • 5.1 What is Diabetes?
  • 5.2 Diabetes Diagnosis and Treatment
    • 5.2.1 Diagnosis
    • 5.2.2 Treatment
  • 5.3 Diabetes Complications

6 Japan Diabetes Epidemiology

  • 6.1 Diabetes Population and Prevalence Rates
  • 6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
  • 6.3 Population and Prevalence Rates by Region
  • 6.4 Population and Prevalence Rates by Gender
  • 6.5 Population and Prevalence Rates by Age Group

7 Japan Diabetes Market

  • 7.1 Market Overview
  • 7.2 Market Performance
  • 7.3 Impact of COVID-19
  • 7.4 Market Forecast
  • 7.5 SWOT Analysis
    • 7.5.1 Overview
    • 7.5.2 Strengths
    • 7.5.3 Weaknesses
    • 7.5.4 Opportunities
    • 7.5.5 Threats
  • 7.6 Value Chain Analysis
  • 7.7 Porter's Five Forces Analysis
    • 7.7.1 Overview
    • 7.7.2 Bargaining Power of Buyers
    • 7.7.3 Bargaining Power of Suppliers
    • 7.7.4 Degree of Competition
    • 7.7.5 Threat of New Entrants
    • 7.7.6 Threat of Substitutes
  • 7.8 Market Breakup by Segment
    • 7.8.1 Japan Oral Antidiabetics Market
      • 7.8.1.1 Historical Market Trends
      • 7.8.1.2 Market Breakup by Class
      • 7.8.1.3 Market Shares of Key Players
      • 7.8.1.4 Market Forecast
    • 7.8.2 Japan Insulin Market
      • 7.8.2.1 Historical Market Trends
      • 7.8.2.2 Market Breakup by Class
      • 7.8.2.3 Market Shares of Key Players
      • 7.8.2.4 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Profiles of Key Players

List of Figures

  • Figure 1: The Impact of Diabetes in the Human Body
  • Figure 2: Diabetes Complications
  • Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2023 & 2032
  • Figure 4: Body Mass Index and Relative risk of Type-2 Diabetes
  • Figure 5: Japan: Total Number of Diabetes Patients (in 000), 2018-2023
  • Figure 6: Japan: Total Number of Diabetes Patients Forecast (in 000), 2024-2032
  • Figure 7: Japan (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2018-2023
  • Figure 8: Japan (Type1 & Type2): Total Number of Diabetes Patients Forecast (in 000), 2024-2032
  • Figure 9: Japan (Urban & Rural): Total Number of Diabetes Patients (in 000), 2018-2023
  • Figure 10: Japan (Urban & Rural): Total Number of Diabetes Patients Forecast (in 000), 2024-2032
  • Figure 11: Japan (Male & Female): Total Number of Diabetes Patients (in 000), 2018-2023
  • Figure 12: Japan (Male & Female): Total Number of Diabetes Patients Forecast (in 000), 2024-2032
  • Figure 13: Japan: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2018-2023
  • Figure 14: Japan: Total Number of Diabetes Patients Forecast by Age Group (20-39), (40-59) & (60-79) (in 000), 2024-2032
  • Figure 15: Japan: Diabetes Drug Industry Overview
  • Figure 16: Japan: Diabetes Drug Market: Sales Value (in Billion US$), 2018-2023
  • Figure 17: Japan: Diabetes Drug Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 18: Japan: Diabetes Drug Market: SWOT Analysis
  • Figure 19: Japan: Diabetes Drug Market: Value Chain Analysis
  • Figure 20: Japan: Diabetes Drug Market: Porters Five Forces Analysis
  • Figure 21: Japan: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2018-2023
  • Figure 22: Japan: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2024-2032
  • Figure 23: Japan: Oral Antidiabetics Market: Sales Value (in Million US$), 2018-2023
  • Figure 24: Japan: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2018 & 2023
  • Figure 25: Japan: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
  • Figure 26: Japan: Oral Antidiabetics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Japan: Insulin Market: Sales Value (in Million US$), 2018-2023
  • Figure 28: Japan: Breakup of Insulin Market by Class (in %), 2023
  • Figure 29: Japan: Insulin Market: Sales Share of Key Players (in %)
  • Figure 30: Japan: Insulin Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Diagnosis of Diabetes
  • Table 2: Global: Diabetes Population Breakup by Country (in 000's), 2023 and 2032
  • Table 3: Japan: Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
  • Table 4: Japan (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
  • Table 5: Japan (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
  • Table 6: Japan (Male & Female): Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
  • Table 7: Japan: Total Prevalence & Number of Diabetes Patients by Age Group (20-39, 40-59, 60-79 - In Millions), 2018, 2023 & 2032
  • Table 8: Japan: Diabetes Drug Market: Competitive Structure